Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

This study has been completed.
Sponsor:
Collaborator:
Staten Island University Hospital
Information provided by (Responsible Party):
Mario Castellanos, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT00665613
First received: April 22, 2008
Last updated: June 5, 2013
Last verified: June 2013
  Purpose

The purpose of this study is to determine if osteoporosis is an unrecognized complication of chronic anticoagulation with warfarin.


Condition
Osteoporosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: The Relationship Between Osteoporosis and Chronic Oral Anticoagulation Therapy With Warfarin

Resource links provided by NLM:


Further study details as provided by North Shore Long Island Jewish Health System:

Primary Outcome Measures:
  • Bone Density [ Time Frame: 5 to 10 years ] [ Designated as safety issue: No ]
    bone density as measured by xray to assess bone strength nd risk of fracture


Enrollment: 300
Study Start Date: October 2004
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

patients on warfarintherapy in the SIUH coumadin center

Criteria

Inclusion Criteria:

  • Patients on warfarin that have had BMD within a year

Exclusion Criteria:

  • Patients on bisphosphates, SERMS, anticonvulsants, estrogens, androgens, calcitonin, hctz and thyroid hormone replacement
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00665613

Locations
United States, New York
Staten Island University Hospital
Staten Island, New York, United States, 10305
Sponsors and Collaborators
North Shore Long Island Jewish Health System
Staten Island University Hospital
  More Information

No publications provided

Responsible Party: Mario Castellanos, Clinical Director of Research for Dept. of Medicine, North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier: NCT00665613     History of Changes
Other Study ID Numbers: 04-054
Study First Received: April 22, 2008
Last Updated: June 5, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by North Shore Long Island Jewish Health System:
warfarin use

Additional relevant MeSH terms:
Osteoporosis
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Warfarin
Anticoagulants
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014